cinaciguat
Small moleculeexperimental
Cinaciguat is an experimental drug for the treatment of acute decompensated heart failure. — Wikipedia
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2007 (NCT00559650)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
Soluble guanylate cyclase alpha1/beta1 complex activator
- Soluble guanylate cyclaseACTIVATOR
Soluble guanylate cyclase activator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)CCCCN(CCc1ccccc1OCc1ccc(CCc2ccccc2)cc1)Cc1ccc(C(=O)O)cc1- Mol. weight
- 565.71 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaCinaciguat ↗
- ChEMBLCHEMBL1236936 ↗
Also known as
- 4-((4-carboxybutyl)(2-((4-phenethylbenzol) oxy)phenethyl)amino)methyl(benzoic) acid
- bay582667
- bay 58-2667
- cinaciguat
- cinaciguat
- cinaciguat
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01064037 | Phase 2 | Apr 1, 2010 | Bayer |
| NCT01065077 | Phase 2 | Mar 1, 2010 | Bayer |
| NCT01067859 | Phase 2 | Mar 1, 2010 | Bayer |
| NCT00559650 | Phase 2 | Dec 1, 2007 | Bayer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 4 | 4 | 1 | 2007 |
1 organizations
Page 1 / 1